Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Palatin Technologies Inc presents positive new data analyses demonstrating efficacy of Bremelanotide in female hypoactive sexual desire disorder


Monday, 24 Feb 2014 07:30am EST 

Palatin Technologies Inc:Presented new analyses from its Phase 2b clinical trial of bremelanotide.Says which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual dysfunction (FSD).Palatin anticipates commencing enrolling patients in Phase 3 clinical trials in the second half of this year. 

Latest Developments for Palatin Technologies Inc

Company Quote

0.85
0.05 +6.25%
2:36pm EST